Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Earnings for Reneo Pharmaceuticals, Inc. (RPHM)
Earnings in 2023 (TTM): $-77,388,000
According to Reneo Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-77,388,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Reneo Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-77,388,000 | $-77,388,000 |
| 2022 | $-51,955,000 | $-50,062,000 |
| 2021 | $-39,770,000 | $-39,770,000 |
| 2020 | $-19,465,000 | $-19,465,000 |
| 2019 | $-12,436,000 | $-12,436,000 |